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Supplementary Table 1. Use of AAV-PHP capsids for efficient transduction across 
specific organs and cell populations. Species/strains, organs, and cell populations examined 
to-date following intravenous administration of AAV-PHP viruses. To restrict gene expression to 
distinct cell types, use rAAV genomes with cell type-specific gene regulatory elements and/or 
Cre- or Flp-dependent recombination schemes (Figs. 2-4 and Table 1). 
Neurons and astrocytes in 
cortical spheroids Ref. 2
GoodAAV-PHP.B
Brain and spinal cord Ref. 3
Ref. 4Rat (Sprague-Dawley), P1 and 6 weeks
Neurons throughout the brain 
and spinal cord
Organs/cell populations 
transduced References
Mouse (C57BL/6J and Cre 
driver lines), ≥6 weeks
Neurons, astrocytes, 
oligodendrocytes, and 
endothelial cells across all brain 
and spinal cord regions 
examined. Transduction in the 
retina occurs with variable 
efficiency across all layers
Ref. 1-3
AAV-PHP.eB Good
AAV-PHP capsid Production Species (strain or line), age injected
Mouse (C57BL/6J), P0-P1
Human iPSCs
Mouse (C57BL/6J, 
C57BL/6NCrl, FVB/NCrl, 
129S1/SvImJ, 129T2/SvEmsJ, 
and Cre driver lines), ≥6 weeks
Rat (Fischer), 6 weeks
Rat (Long Evans), 4 weeks
Rat (Sprague-Dawley), 6 weeks
AAV-PHP.A Poor Mouse (C57BL/6J), 6 weeks Astrocytes throughout the brain
Sensory neurons, peripheral 
ganglia (sympathetic, nodose, 
dorsal root, and cardiac 
ganglia), and the myenteric and 
submucosal plexus of the 
enteric nervous system. Robust 
transduction of heart muscle, 
skeletal muscle, and circular 
and longitudinal muscle of the 
digestive tract, as well as the 
liver and lungs
AAV-PHP.S Good Ref. 5, this workMouse (C57BL/6J and Cre driver lines), 6-8 weeks
Ref. 2
Similar to AAV-PHP.B but with 
increased efficiency of neuronal 
transduction
Ref. 5, this work
Ref. 6
 Supplementary Table 2. Transfection calculator. This is an interactive calculator and 
provided as an Excel file (see Step 2 and REAGENT SETUP). 
 
 
Supplementary Table 3. Pouring the iodixanol density step solutions. Determine the 
number of gradients needed and prepare the iodixanol density step solutions (see REAGENT 
SETUP). The 15% step contains high salt to destabilize ionic interactions between viral particles 
and cell proteins in the clarified lysate7. In Step 16 (option B), prepare more step solution than is 
needed (see REAGENT SETUP). 
 
Supplementary Table 4. Titration calculator. This is an interactive calculator and provided as 
an Excel file (see Step 42 and REAGENT SETUP). 
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% Solution (ml) 1 2 4 6 8
DPBS + high salt 5.0 9.9 19.8 29.7 39.6
60% iodixanol 1.7 3.3 6.6 9.9 13.2
DPBS + low salt 3.9 7.7 15.4 23.1 30.8
60% iodixanol 2.8 5.5 11.0 16.5 22.0
Phenol red 0.1 0.1 0.2 0.3 0.4
DPBS + low salt 1.8 3.7 7.3 11.0 14.7
60% iodixanol 3.7 7.3 14.7 22.0 29.3
60% iodixanol 5.5 11.0 22.0 33.0 44.0
Phenol red 0.1 0.1 0.2 0.3 0.4
Number of gradientsStepVolume of each step 
per gradient (ml)
40
60
6
6
5
5
15
25
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